MIRANSERTIB
Miransertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against RAC-gamma serine/threonine-protein kinase, RAC-beta serine/threonine-protein kinase, and RAC-alpha serine/threonine-protein kinase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
7 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Proteus syndrome | D016715 | Orphanet_744 | Q87.3 | 2 | 3 | — | — | 1 | 5 |
| Syndrome | D013577 | — | — | 2 | 3 | — | — | — | 4 |
| Proteus infections | D011512 | EFO_1001130 | — | 2 | 3 | — | — | — | 4 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 2 | — | — | — | — | 2 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 1 | — | — | — | — | 1 |
| Lymphoma | D008223 | — | C85.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vascular malformations | D054079 | — | — | — | — | — | — | 1 | 1 |
| Growth disorders | D006130 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | MIRANSERTIB |
| INN | miransertib |
| Description | Miransertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against RAC-gamma serine/threonine-protein kinase, RAC-beta serine/threonine-protein kinase, and RAC-alpha serine/threonine-protein kinase. |
| Classification | Small molecule |
| Drug class | serine/threonine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 101409-76-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297188 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | T1DQI1B52Y (ChemIDplus, GSRS) |
Target
Agency Approved
AKT2
AKT2
Organism
Homo sapiens
Gene name
AKT2
Gene synonyms
NCBI Gene ID
Protein name
RAC-beta serine/threonine-protein kinase
Protein synonyms
murine thymoma viral (v-akt) homolog-2, PKB beta, Protein kinase Akt-2, Protein kinase B beta, putative v-akt murine thymoma viral oncoprotein 2, rac protein kinase beta, RAC-PK-beta, v-akt murine thymoma viral oncogene homolog 2
Uniprot ID
Mouse ortholog
Akt2 (11652)
RAC-beta serine/threonine-protein kinase (Q60823)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 359 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use